Previous 10 | Next 10 |
2024-03-06 17:42:05 ET More on Zymeworks Zymeworks: A Strong Buy Amidst Zanidatamab's Promising Developments Zymeworks Non-GAAP EPS of -$0.16 beats by $0.28, revenue of $16.92M misses by $0.74M Read the full article on Seeking Alpha For further details see: ...
2024-03-06 17:09:23 ET Summary Baker Brothers' 13F portfolio value decreased from $17.35B to $8.79B. The largest five stakes in the portfolio are Incyte, BeiGene, ACADIA Pharma, Madrigal Pharma, and Rhythm Pharma. New stakes include Cerevel Therapeutics, while stake disposals ...
2024-03-06 16:20:17 ET More on Zymeworks Zymeworks: A Strong Buy Amidst Zanidatamab's Promising Developments Zymeworks: Key Readout For Zanidatamab This Year And ADC Pipeline Expansion Zymeworks: Stock Emerges From Nearly 2 Years In The Doldrums, Thanks To An ADC Tai...
Reported $456.3 million in cash resources as of December 31, 2023, which when combined with certain anticipated regulatory milestone payments provides projected cash runway into 2H 2027 Initiation of rolling biologics license application (BLA) filing with the FDA for zanidatam...
Klepierre (KLPEF) is expected to report for Q4 2023 comScore Inc. (SCOR) is expected to report $0.8 for Q4 2023 Universal Stainless & Alloy Products Inc. (USAP) is expected to report for Q4 2023 FAT Brands Inc. (FAT) is expected to report $-1.55 for Q4 2023 Jet.AI Inc. (JTAI) ...
2024-03-05 17:35:47 ET Major earnings expected after the bell on Wednesday include: Inovio Pharmaceuticals ( INO ) TriplePoint Venture Growth BDC Corp. ( TPVG ) Curaleaf Holdings ( OTCPK:CURLF ) Vermilion Energy ( VET ) Hudson Technologies ( HDSN ) ...
2024-03-05 17:35:34 ET More on Zymeworks Zymeworks: A Strong Buy Amidst Zanidatamab's Promising Developments Zymeworks: Key Readout For Zanidatamab This Year And ADC Pipeline Expansion Zymeworks: Stock Emerges From Nearly 2 Years In The Doldrums, Thanks To An ADC Tai...
Five abstracts accepted for poster presentation highlight company’s differentiated antibody-drug conjugate and multispecific antibody clinical product candidates Strong preclinical activity across multiple FRα-expressing indications for ZW191, a FRα-targeting antibo...
2024-02-24 19:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-02-15 10:04:10 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Investing in small-cap stocks offers multiple advantages for those looking to diversify their portfolios with potential high-growth opportunities efficiently. Small-cap stocks strike a unique b...
News, Short Squeeze, Breakout and More Instantly...
VANCOUVER, British Columbia, July 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that manage...
VANCOUVER, British Columbia, June 17, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the Un...
Pursuant to the terms of the licensing agreement between Zymeworks and BeiGene, Zymeworks is entitled to receive an $8 million milestone payment from BeiGene and remains eligible to receive up to $164 million based on additional milestones plus royalties on product sales A Biologics License A...